Therapeuticsmd Inc (TXMD) 5.46 $TXMD
Trade-Ideas: TherapeuticsMD (TXMD) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Sep 12, 9:05AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a strong on high relative volume candidate
4 Stocks Under $10 Making Big Moves
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Aug 13, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
TherapeuticsMD Announces Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 3:06PM CDT
--Combination and VVA Hormone Therapy Programs Advancing on Schedule
TherapeuticsMD to Hold Second Quarter 2014 Financial Results Conference Call and Webcast on August 6
Business Wire - Fri Aug 01, 6:00AM CDT
TherapeuticsMD (NYSE MKT:TXMD), a women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss its second quarter financial and business results Wednesday, August 6. The conference call and webcast will take place at 4:30 p.m. EDT and will be hosted by Robert Finizio, Chief Executive Officer, and Dan Cartwright, Chief Financial Officer.
TherapeuticsMD plans to issue USD40m shares in public offering
M2 - Wed Jul 30, 6:37AM CDT
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Tuesday that it intends to start its public offering of USD40m shares of its common stock.
TherapeuticsMD Announces Pricing of Offering of Common Stock
Business Wire - Wed Jul 30, 6:01AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company"
announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions.
TherapeuticsMD Announces $40 Million Offering of Common Stock
Business Wire - Tue Jul 29, 3:13PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company" today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock.
Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis
PR Newswire - Tue Jul 22, 8:10AM CDT
On Monday, July 21, 2014, the NASDAQ Composite ended at 4,424.70, down 0.17%, the Dow Jones Industrial Average declined 0.28%, to finish the day at 17,051.73, and the S&P 500 closed at 1,973.63, down 0.23%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 707.91, down 0.39%, while the index has advanced 6.22% in the previous three months. Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), TherapeuticsMD Inc. (NYSE MKT: TXMD), AstraZeneca PLC (NYSE: AZN), Zogenix Inc. (NASDAQ: ZGNX), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at:
TherapeuticsMD Investor Update; BrokerBank Securities, Inc. Offers Insight on Long-Term Uncertainty Amid Short-Term Catalysts
PR Newswire - Tue Jul 15, 1:30PM CDT
According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five years.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jul 13, 6:30AM CDT
It was a rough week on Wall Street, with the market moving lower, but there were plenty of stocks still moving higher. Let's take a closer look at five of this past week's biggest scorchers. Company July 11 Weekly Gain ...
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD)
at The Street - Thu Jul 10, 9:56AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a "dead cat bounce" (down big yesterday but up big today) candidate
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why TherapeuticsMD Inc. Stock Grew Wings
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TherapeuticsMD , a drug manufacturer...
Why TherapeuticsMD (TXMD) Stock Is Surging Today
at The Street - Tue Jul 08, 9:39AM CDT
TherapeuticsMD (TXMD) surged Tuesday after FBR Capital initiated coverage on the pharmaceutical company with an "outperform" rating and a $34 price target.
Trade-Ideas: TherapeuticsMD (TXMD) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Sep 12, 9:05AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a strong on high relative volume candidate
4 Stocks Under $10 Making Big Moves
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Aug 13, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
TherapeuticsMD Announces Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 3:06PM CDT
--Combination and VVA Hormone Therapy Programs Advancing on Schedule
TherapeuticsMD to Hold Second Quarter 2014 Financial Results Conference Call and Webcast on August 6
Business Wire - Fri Aug 01, 6:00AM CDT
TherapeuticsMD (NYSE MKT:TXMD), a women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss its second quarter financial and business results Wednesday, August 6. The conference call and webcast will take place at 4:30 p.m. EDT and will be hosted by Robert Finizio, Chief Executive Officer, and Dan Cartwright, Chief Financial Officer.
TherapeuticsMD plans to issue USD40m shares in public offering
M2 - Wed Jul 30, 6:37AM CDT
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Tuesday that it intends to start its public offering of USD40m shares of its common stock.
TherapeuticsMD Announces Pricing of Offering of Common Stock
Business Wire - Wed Jul 30, 6:01AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company"
announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions. TherapeuticsMD Announces $40 Million Offering of Common Stock
Business Wire - Tue Jul 29, 3:13PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company"
today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock. Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis
PR Newswire - Tue Jul 22, 8:10AM CDT
On Monday, July 21, 2014, the NASDAQ Composite ended at 4,424.70, down 0.17%, the Dow Jones Industrial Average declined 0.28%, to finish the day at 17,051.73, and the S&P 500 closed at 1,973.63, down 0.23%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 707.91, down 0.39%, while the index has advanced 6.22% in the previous three months. Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), TherapeuticsMD Inc. (NYSE MKT: TXMD), AstraZeneca PLC (NYSE: AZN), Zogenix Inc. (NASDAQ: ZGNX), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at:
TherapeuticsMD Investor Update; BrokerBank Securities, Inc. Offers Insight on Long-Term Uncertainty Amid Short-Term Catalysts
PR Newswire - Tue Jul 15, 1:30PM CDT
According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five years.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jul 13, 6:30AM CDT
It was a rough week on Wall Street, with the market moving lower, but there were plenty of stocks still moving higher. Let's take a closer look at five of this past week's biggest scorchers. Company July 11 Weekly Gain ...
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD)
at The Street - Thu Jul 10, 9:56AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a "dead cat bounce" (down big yesterday but up big today) candidate
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why TherapeuticsMD Inc. Stock Grew Wings
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TherapeuticsMD , a drug manufacturer...
Why TherapeuticsMD (TXMD) Stock Is Surging Today
at The Street - Tue Jul 08, 9:39AM CDT
TherapeuticsMD (TXMD) surged Tuesday after FBR Capital initiated coverage on the pharmaceutical company with an "outperform" rating and a $34 price target.
